rs4810424 — R3HDML R3HDML rs4810424

Intronic variant tagging the HNF4A P2 promoter risk haplotype; C allele carriers show reduced pancreatic beta-cell HNF4A expression and modestly elevated type 2 diabetes risk

See your personal result for R3HDML

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HNF4A P2 Promoter: A Beta-Cell Transcription Signal

The R3HDML gene on chromosome 20q13 sits immediately adjacent to a well-characterized regulatory landmark: the P2 promoter of HNF4A (| Hepatocyte Nuclear Factor 4-alpha, a transcription factor critical for pancreatic islet development and insulin secretion). rs4810424 falls within an R3HDML intron, but its biological significance comes from being a reliable tag for the HNF4A P2 promoter risk haplotype — a cluster of SNPs (rs4810424, rs1884613, rs1884614, rs2144908) in nearly complete linkage disequilibrium (D' > 0.97, r² > 0.95) that were originally identified in Finnish and Ashkenazi Jewish populations.

The Mechanism

HNF4A is an orphan nuclear receptor | A transcription factor that binds DNA to regulate gene expression; called "orphan" because its natural ligand was originally unknown that controls genes governing glucose-stimulated insulin secretion, gluconeogenesis, and beta-cell maintenance. Critically, while both the P1 and P2 promoters drive HNF4A expression in liver cells, pancreatic islets rely almost exclusively on the P2 promoter. Common variants tagging the P2 haplotype are therefore expected to alter HNF4A expression disproportionately in the tissue most relevant to type 2 diabetes: the insulin-secreting beta cell.

The P2 haplotype risk alleles are associated with reduced HNF4A transcript levels in islets, impairing the transcriptional cascade that drives expression of insulin, glucose transporter-2 (GLUT2), L-pyruvate kinase, and other metabolic coupling genes. The functional consequence is a blunted insulin secretory response to glucose — a mechanism consistent with the OGTT-based associations observed in Japanese and Thai cohorts | Tokunaga et al., Endocrine J, 2008, PMID 18654034; Jongjaroenprasert et al., Acta Diabetol, 2007, PMID 17805472.

The Evidence

The original discovery came from the FUSION study in Finland, where Silander et al.11 Silander et al.
Silander K et al. Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes. Diabetes, 2004 identified the P2 haplotype association with T2D (OR 1.33, 95% CI 1.06-1.65, p = 0.011) in 495 Finnish affected sibling pairs, with independent replication in Ashkenazi Jewish samples.

A large UK replication study Weedon et al.22 Weedon et al.
Weedon MN et al. Common variants of the hepatocyte nuclear factor-4alpha P2 promoter are associated with type 2 diabetes in the UK population. Diabetes, 2004 confirmed the association in 5,256 Caucasians (OR 1.15, 95% CI 1.02-1.33, p = 0.02). The smaller effect size in the UK compared with Ashkenazi populations (OR ~1.7) suggests the causal variant within the haplotype block differs in frequency or is modified by population background.

In the prospective STOP-NIDDM trial33 STOP-NIDDM trial
Andrulionyte L et al. SNPs of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. J Mol Med, 2006, female carriers of the C allele at rs4810424 had a 1.7-fold elevated risk of converting from impaired glucose tolerance to diabetes (OR 1.7, 95% CI 1.09-2.66, p = 0.020), while no association was detected in men. A combined Swedish-Finnish cohort Holmkvist et al.44 Holmkvist et al.
Holmkvist J et al. Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes, 2008 found rs4810424 predicted future T2D (HR 1.3, 95% CI 1.0-1.6, p = 0.03) across 17,831 participants.

The association is notably population-specific: the risk effect is strongest in Ashkenazi Jewish individuals, moderate in Scandinavians and Finns, and not consistently replicated in UK Caucasians. The C allele is also far more common in East Asian populations (~44% vs ~17% in Europeans), though its T2D association in Asian cohorts is primarily mediated by rs1884614 and rs2144908 rather than rs4810424 itself.

Practical Actions

Carriers of the risk haplotype — particularly CC homozygotes — have a modestly elevated risk of beta-cell secretory insufficiency that is amenable to dietary and monitoring strategies. A diet that reduces the post-meal glucose load (lower glycemic index, reduced refined carbohydrate) directly offsets the beta-cell demand amplified by impaired HNF4A expression in islets. Prospective data from the STOP-NIDDM trial also showed that acarbose — an alpha-glucosidase inhibitor — partially offset the progression to T2D in high-risk individuals with impaired glucose tolerance, consistent with a glucose-spike mechanism.

Interactions

rs4810424 is in high LD with rs2144908 (r² ≈ 0.97), rs1884614, and rs1884613 within a ~15 kb P2 haplotype block. Carrying risk alleles at multiple haplotype members compounds the beta-cell expression deficit but does not add independent risk beyond the haplotype signal. Separately, published data show an interaction between HNF4A rs2144908 and KCNJ11 E23K (rs5219) — carriers of both risk variants show markedly greater impairment of insulin secretion than either alone, consistent with additive disruption of the ATP- sensitive potassium channel pathway that HNF4A transcriptionally regulates.

Nutrient Interactions

dietary carbohydrate altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal HNF4A Haplotype Normal

Normal HNF4A P2 promoter haplotype

The GG genotype means you are homozygous for the reference allele at this position, which serves as a tag for the absence of the HNF4A P2 risk haplotype. HNF4A drives expression of insulin, GLUT2, and other beta-cell metabolic coupling genes almost exclusively through its P2 promoter in pancreatic islets. Without the risk haplotype, this regulatory axis is intact and your insulin secretory response to glucose is not expected to be impaired through this mechanism.

CG P2 Haplotype Carrier Intermediate

One copy of the HNF4A P2 risk haplotype

Heterozygous carriers have one copy of the P2 risk haplotype. The HNF4A P2 promoter is the primary driver of HNF4A expression in pancreatic islets; risk-haplotype alleles are associated with reduced islet HNF4A transcript levels, which blunts glucose- stimulated insulin secretion. With one copy, the functional deficit is partial — the unaffected allele continues to drive normal expression from the other chromosome. The association with T2D progression is consistent but modest in most European populations; stronger effects are seen in Ashkenazi Jewish and Scandinavian cohorts.

CC P2 Haplotype Homozygote High Risk

Two copies of the HNF4A P2 risk haplotype

CC homozygotes carry the P2 risk haplotype on both chromosomes, meaning both copies of the HNF4A P2 promoter carry alleles associated with reduced islet expression. HNF4A controls transcription of insulin, GLUT2, L-pyruvate kinase, aldolase B, and mitochondrial uncoupling protein-2 — all critical components of the glucose-sensing and insulin secretion machinery in beta cells. With both alleles impaired, the compensatory capacity of the unaffected chromosome present in heterozygotes is absent.

The STOP-NIDDM trial demonstrated that the OR for conversion from impaired glucose tolerance to T2D was 1.7 for C allele carriers overall; the expected effect in homozygous carriers is larger under an additive model, though direct CC-specific ORs are not reported in all studies due to the low frequency of this genotype. The population-specific nature of the risk means the absolute magnitude varies: the effect is most pronounced in Ashkenazi Jewish individuals and Scandinavians, while data from UK Caucasians show a smaller signal.